FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market

The case relates to Forest Laboratories Inc. and six generic drug manufacturers’ alleged efforts to delay competition with Bystolic, Forest’s brand-name high blood pressure drug.

Metadata
Provider: 
FTCFTC
URL: 
https://www.ftc.gov/news-events/news/press-releases/2023/06/ftc-files-amicus-brief-bystolic-antitrust-litigation-supporting-competition-hypertension-drug-markethttps://www.ftc.gov/news-events/news/press-releases/2023/06/ftc-files-amicus-brief-bystolic-antitrust-litigation-supporting-competition-hypertension-drug-market
Retrieved on: 
Wednesday, June 21, 2023
Information
Tags: 
Supreme, Actavis, Laboratory, Commission, List, Supreme Court of the United Kingdom, United States Court of Appeals for the Second Circuit, Blog, Social media, Federal Trade Commission, Complaint, District court, FTC, Supreme court, Curia Julia, Douglas v. U.S. District Court ex rel Talk America, News, Federal Trade Commission v. Meta Platforms, Inc., Nebivolol
Geotags: 
NEW YORK, FOREST
Summary
Key Points: 
  • The case relates to Forest Laboratories Inc. and six generic drug manufacturers’ alleged efforts to delay competition with Bystolic, Forest’s brand-name high blood pressure drug.
  • In the Commission’s brief, the FTC urged the appeals court to reverse a district court’s decision to dismiss the case and recognize that large reverse payments Forest made to the generic companies may violate the antitrust laws.
  • Unless corrected, the district court’s ruling threatens to impair the effective enforcement of antitrust laws in the pharmaceutical industry, the FTC told the Second Circuit.
  • For the latest news and resources, follow the FTC on social media, subscribe to press releases and read our blog.
Copyright: 
2023 FTC. All Rights Reserved.